Future research should focus on exploring alternative targets, such as CD56, TCL1, and recurrent genetic alterations (e.g., TET2, ASXL1, TP53), to enhance treatment specificity and efficacy, ultimately broadening the clinical applicability of precision medicine in BPDCN [23]. The gene discussed is TET2; the disease is CD4+/CD56+ hematodermic neoplasm.